37 results
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
requiring establishment and maintenance of effective disclosure and financial controls, changes in corporate governance practices, proxy access and “say … . Directors, Executive Officers and Corporate Governance
Information required by this item will be contained in our definitive proxy statement to be filed
424B4
EVOK
Evoke Pharma Inc
9 Feb 24
Prospectus supplement with pricing info
5:14pm
an additional annual cash retainer of $8,000, and the chair of the nominating and corporate governance committee received an additional annual cash … annual cash retainer of $4,000 and nominating and corporate governance committee members received an additional annual cash retainer of $2,750.
Each non
PRE 14A
h3k6n1
12 Mar 21
Preliminary proxy
8:30am
8-K
EX-1.1
yie59
14 Jan 21
Evoke Pharma Announces Proposed Public Offering of Common Stock
5:22pm